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Abstract: Cancer metabolism is the focus of intense research, which witnesses its key role 
in human tumors. Diabetic patients treated with metformin exhibit a reduced incidence of 
cancer and cancer-related mortality. This highlights the possibility that the tackling of 
metabolic alterations might also hold promising value for treating cancer patients. Here, we 
review the emerging role of metformin as a paradigmatic example of an old drug used 
worldwide to treat patients with type II diabetes which to date is gaining strong in vitro and 
in vivo anticancer activities to be included in clinical trials. Metformin is also becoming  
the focus of intense basic and clinical research on chemoprevention, thus suggesting  
that metabolic alteration is an early lesion along cancer transformation. Metabolic 
reprogramming might be a very efficient prevention strategy with a profound impact on 
public health worldwide. 
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1. Introduction: The Evolution of Metformin 
Currently, the anti-hyperglycemic agent metformin (dimethylbiguanide) is the front-line therapy for 
patients with type II diabetes (T2D) worldwide. Its medical history dates back to the use of  
Galega officinalis (the French lilac), which was utilized in Chinese medicine and also in medieval 
Europe to treat halitosis and polyurea [1,2]. Later, this plant was also described to treat symptoms of 
diabetes up until the early 1930s in France [3]. Research in the late 1800s found that  
Galega officinalis was rich in guanidine, which had hypoglycemic proprieties in animals that may 
explain the plants anti-diabetic action [4]. However, the clinical use of guanidine was found to be 
toxic, but an isoprenyl derivative, known as galegine, had fewer side-effects and was used for the 
treatment of diabetes in humans in the 1920s [5]. At around the same time, dimethylbiguanide (now 
known as metformin) was also synthesized and effectively lowered blood glucose levels in vivo [6], 
but its clinical application in treating diabetes was hindered by the discovery of insulin during the same 
decade. Not until the 1950s was metformin, as well as the more potent biguanide derivatives 
phenformin and buformin, used clinically for the treatment T2D [7]. Initially, the latter drugs were 
more widely used, however phenformin and buformin were correlated with life-threatening lactic 
acidosis which led to their discontinuation in the 1970s [8]. Meanwhile, metformin use began to thrive 
due to its high therapeutic index. 
Clinically it has been shown that metformin works to suppress hepatic gluconeogenesis, thereby 
lowering blood glucose levels in patients with poorly managed T2D [9]. It should be noted though, that 
the molecular mechanisms by which metformin achieves these effects are still largely debated. 
However, a prevailing premise is that due to its positive charge, metformin accumulates within the 
cellular mitochondrial matrix and inhibits complex I of the mitochondrial respiratory chain (as does 
phenformin), which results in a backlog of ATP production [10,11]. This in turn, leads to the activation 
of the energy sensing enzyme AMP-activated protein kinase (AMPK), which inhibits energy 
consuming processes and switches cellular metabolism towards energy production to restore energy 
homeostasis [12]. Indeed, metformin-mediated AMPK activation results in modulation of downstream 
targets that enhance glucose uptake into skeletal muscle [13] and inhibit genes that regulate hepatic 
gluconeogenesis [14], which may explain the abovementioned clinical observations of this drug. 
Due to the safety profile of metformin, this agent has gone onto numerous clinical trials for the 
management of other disease pathologies, including polycystic ovarian syndrome [15,16] and 
metabolic syndrome [17] with some success. More recently, there has been a great deal of interest in 
the ability of metformin in cancer chemoprevention and therapy [18]. An initial epidemiological report 
conducted by Evans et al. [19] gained the attention of the oncology field when they found that diabetic 
patients taking metformin, as compared to other patients treated with other hypoglycemic therapies, 
had a significant reduction in cancer risk. These results sparked widespread metformin research, 
ranging from the mechanistic studies to determine its anti-proliferative effect in cancer cells, to clinical 
trials in non-diabetic patients with various malignancies [20,21]. 
An additional benefit for metformin use in oncology is that its known to modulate energy 
metabolism, which is a topic that is re-emerging in the cancer field. For instance, cancer cells are often 
more metabolically active than surrounding non-malignant tissue. As a consequence of this phenotype, 
any opposition to glucose utilization by low-energy mimetics such as metformin may inhibit tumor 
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proliferation. In fact, recent studies have indicated that tumors carrying mutations in metabolic stress 
regulators such as LKB1 and p53 undergo substantial apoptosis when treated with biguanides [22–24]. 
Herein, we review the metabolomic effects of metformin and highlight its possibilities and pitfalls 
for cancer chemoprevention and treatment. We begin by identifying the metabolic profile of cancer 
cells and outline the molecular mechanisms that contribute to altered energy metabolism. We then 
provide insight into metformin effects on these metabolic pathways and its role in the inhibition of 
tumor growth and proliferation, particularly at the level of microRNA (miRNA) signaling. Finally, we 
summarize the past and current preclinical and clinical trials that support the use of metformin for 
combination cancer therapy and chemoprevention. 
2. Metabolism and Cancer 
Tumorigenesis is a multistep process and reflects genetic alterations that drive cancer progression. 
A decade ago six essential hallmarks that represent the essential alterations in cancer cell physiology: 
self-sufficiency in growth signals, tissue invasion and metastasis, evasion of apoptosis, sustained 
angiogenesis, limitless replicative potential, insensitivity to anti-growth signals were described [25]. 
Currently, a revival in research on tumor metabolism also suggests that there is another important 
hallmark that characterized cancer cells: altered cell bioenergetic pathways [26]. 
Tumor cells often display alterations in their energy metabolism to support rapid growth.  
For example, unlike normal cells, tumors have enhanced rates of glucose uptake for glycolytic ATP 
generation; a truncated tricarboxylic acid (TCA) cycle utilized to produced acetyl-CoA used for the 
synthesis of fatty acids, cholesterol and isoprenoids; and a increase in protein and DNA synthesis due 
to their high rate of metabolism [27]. This physiological process was first observed by Otto Warburg 
almost a century ago, where he observed that cancer cells preferentially utilize glucose through aerobic 
glycolysis even in an oxygen rich environment [28]. This mechanism of rapid glucose utilization 
through glycolysis for energy and macromolecule synthesis was later termed the Warburg effect. 
The Warburg effect is modulated by the activity of well-known oncogenes and tumor suppressors 
that are deregulated during the early stages of carcinogenesis. 
For example, the hypoxia-inducible factor 1 (HIF-1) drives the increase of glycolysis by modulating 
the transcription of the cell-surface transporter of glucose GLUT1 [29] and inhibits mitochondrial 
respiration through the activation of the pyruvate dehydrogenase kinase (PDK) [30,31] that in turn 
induces a decrease in Acetyl-CoA levels through the inhibition of the mitochondrial pyruvate 
dehydrogenase (PDH) complex (Figure 1). Independently from HIF-1, during normoxia, high levels of 
Akt can also increase the glycolytic flux. This event is sufficient to trigger aerobic glycolysis due to 
the increase in glucose uptake [32] and to the activation of hesokinase 2 (HK2) [33]. 
An important oncogene involved in metabolism is c-Myc, which is able to enhance directly the 
glycolytic pathway (Figure 1) modulating the expression of several genes involved in this process and 
indirectly regulate other transcription factor. In particular, it is well known that lactate dehydrogenase 
A (LDHA), the enzyme that converts pyruvate to lactate, is transcriptionally controlled by c-Myc [34].  
In addition, c-Myc promoted mitochondrial biogenesis thereby increasing mitochondrial function [34,35]. 
The c-Myc-control of the mitochondrial function is important to generate substrates for 
macromolecular biosynthesis that guarantee a rapid cells proliferation, a typical hallmark of cancer 
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cells and the Warburg effect. The paradoxical production of lactate together with the activation of the 
TCA cycle could be explained by another metabolic process mediated by c-Myc: the catabolism of 
glutamine [36,37] (Figure 1). 
Figure 1. The role of oncogenes, tumor suppressors and microRNAs in cancer metabolism. 
 
Conversely, the tumor suppressor p53 is able to suppress glycolysis by modulating the expression 
of two important genes, the glycolytic inhibitory protein TP53-induced glycolysis and apoptosis 
regulator (TIGAR) [38,39], and cytochrome c oxidase 2 subunit (SCO2) [39]. The latter stimulates 
mitocondrial oxidative phosphorylation through complex IV of the electron transport chain [39] (Figure 1). 
Furthermore, the overexpression of genes involved in fatty acid synthesis, such as the fatty acid 
synthase (FASN), acetyl-CoA carboxylase alpha (ACACA) and, the ATP citrate lyase (ACLY) can 
induce the development and progression of cancer [40]. Overexpression of FASN, in fact, is a predictor 
of recurrence in stage I breast carcinoma [41], lung carcinoma [42], endometrial carcinoma [43] 
patients and correlate with a worst prognosis in breast carcinoma [44] and ovarian carcinoma [45] 
patients. In addition, ACACA is also known to be upregulated and support the proliferation of many 
cancers including breast, colon, lung, and liver [46]. 
Emerging studies have identified that microRNAs may also play a role in regulating metabolic 
processes. Indeed, glucose metabolism seems to be regulated by microRNAs through the modulation 
of the insulin production and secretion. 
MicroRNAs are short and stable non coding RNAs, 18–25 nucleotides long, that modulate the 
translation of mRNA of coding genes by binding their 3′-untraslated regions [47]. This generally leads 
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to the degradation of target mRNA, thereby effectively reducing the levels of the gene products. 
Interestingly, one microRNA can bind a plethora of mRNAs that in turn can be bonded by several 
microRNAs. For these reasons the microRNA modulation represents an important mechanism through 
which various stimuli can rapidly modify important cellular processes, by targeting multiple genes at 
the same time [47]. 
Alterations of microRNA processing may also represent a way to perturbate cellular homeostasis. 
In fact, down-regulation of DICER, the RNAse III that together with the ribonuclease DROSHA are 
primarily implicated in the microRNAs processing, was shown to be a pro-tumorigenic event.  
This leads to enhance the epithelial to mesenchymal transition and the metastatic dissemination of 
breast cancer cells [48]. Moreover, lower expression of DICER is correlated with a worst prognosis of 
breast, lung and ovarian cancer patients [49,50]. 
The emerging role of microRNAs in lipid homeostasis has focused on finding possible strategies to 
block the activity of specific microRNAs by targeting with antisense oligos. The most known example 
is miR-122. It represents the most abundant microRNA in the liver and plays an important role in 
hepatic cholesterol and lipid metabolism (Figure 1). The antisense targeting of miR-122 into mice 
resulted in a decrease of plasma cholesterol levels [51,52] through the indirect modulation of genes 
involved in cholesterol biosynthesis, such as 3-hydroxy-3-methylglutaryl-CoA synthase 1 (Hmgcs1), 
3-hydroxy-3-methylglutaryl-CoA reductase (Hmgcr) and 7-dehydrocholesterol reductase (Dhcr7) [52].  
Similar to the miR-122 family of microRNAs, miR-33 is implicated as a potential target for 
metabolic disorders treatment. miR-33a and miR-33b are intronic microRNAs which are encoded 
together with their host genes, the sterol-regulatory element-binding proetein 1 (Srebp1) and  
2 (Srebp2). The Srebp genes act coordinately with their intronic microRNAs to regulate cholesterol, 
triglyceride and lipid homeostasis (Figure 1). 
In particular, Srebp2 and its intronic microRNA, miR-33a, regulate the cholesterol homeoastasis by 
modulating transcriptionally and post-transcriptionally the activity of genes involved in the cellular 
cholesterol export, such as the ATP-binding cassette (ABC) transporter ABCA1 and ABCG1 [53–55]. 
While, Srebp1 and miR-33b regulate the lipid homeostasis and the insulin signaling by modulating the 
activity of key genes involved in these process. However, there is not a specific separation of function 
between miR-33a and miR-33b. The two microRNAs shave overlapping gene targets through their 
similar mature sequence that differs of only two nucleotides. Several studies confirmed this evidence; 
thus, there is an extensive collaboration between miR-33a and miR-33b and their host genes (Figure 1). 
miR-33-targeting antisense oligonucletotides appears to be a novel therapy approach for cardio 
metabolic disorders, such as atherosclerosis. The inhibition of ABCA1 by miR-33 induced an efflux of 
cholesterol from peripheral tissues to the liver and a consequent reduction of circulating high-density 
lipoprotein-cholesterol (HDL-C) [53]. In addition, the inhibition of the endogenous levels of miR33 in 
human liver cells induces fatty acid degradation, through the lack of modulation in the expression of 
genes involved in the oxidation of fatty acid [56,57]. Moreover, miR-33 have been involved in the 
post-transcriptional modulation of other mRNAs involved in the regulation of lipid and glucose 
metabolism, such as the α1 subunit of AMP-activated protein kinase (AMPKα1) [56,58,59]. The role 
of this enzyme in regulating energy homeostasis and tumor suppression will be discussed later in this 
review, as well as sirtuin 6 (Sirt6) [56,60]. 
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However, Blandino and colleagues have shown in breast cancer cell lines a direct interaction 
between the miR-33a and the 3′-utr region of Myc mRNA. They suggested that the anticancer 
metabolic effects induced by metformin in breast cancer cell lines were, also a direct consequence of 
the Myc inhibition mediated by the up regulation of miR-33a. Metformin was not longer able to induce 
metabolic changes in breast cancer cell lines overexpressing c-Myc protein [61]. This evidence 
suggests that any anti-microRNA therapy must be designed for a specific tissue in a way to reduce the 
possible side effects. 
The emerging role of altered metabolism in cancer development and progression makes it a target 
for a specific anticancer treatment. Metformin could be a candidate for metabolic targeted therapy.  
In fact, metformin is known to impinge on many metabolic pathways that result deregulated during 
cancer development. Indeed, its action modulates the activity of several key proteins whose anticancer 
roles will be extensive discussed in the following chapters. 
3. Metformin Mechanism of Action 
The mechanisms of metformin action are still being elucidated, however several studies underline 
its influence in the cellular energy balance. For example, multiple lines of evidence suggest that the 
action of metformin passes, largely, through the activation of the AMPK [62], although recent 
evidence has also suggested that the effects of this drug may be AMPK-independent [63]. With respect 
to the former hypothesis, metformin has been described to increase the cellular AMP:ATP ratio 
inhibiting the complex I of mitochondrial respiratory chain [10,64]. This change in AMP:ATP ratio and 
the consequence ATP depletion is sensed by AMPK, the master regulator of cellular energy homeostasis. 
AMPK consists of three subunits, α, β and γ, and each subunit has at least two isoforms [65]. 
Activation of AMPK involves AMP binding to regulatory sites on the γ subunits. This causes 
conformational changes that allosterically activate the enzyme and inhibit dephosphorylation on  
Thr-172 within the activation loop of the catalytic α subunit [66,67]. The AMP binding on the  
γ subunit is not enough to activate AMPK. Liver kinase B1 (LKB1), a tumor suppressor gene, is 
required to phosphorylate the α subunit of AMPK at Thr-172 to activate the enzyme [68].  
Once activated, AMPK regulates a pool of substrates which represents the key enzymes in the 
catabolic pathways and inhibits ATP-consuming anabolic pathways. AMPK also controls enzymes 
involved in cell cycle and protein metabolism. 
Many studies indicate that loss of LKB1 impairs the ability of metformin to activate AMPK and 
maintain plasma glucose and insulin homeostasis (references). Moreover, patients affected by 
Polycystic Ovarian Syndrome (PCOS) showed a different ovulatory response once treated with 
metformin basing on their polymorphism in the LKB1 gene [69]. Hardie suggests that the LKB1 and 
AMPK pathway functions as a cellular energy-sensing checkpoint that controls cell growth and 
proliferation according to the availability of fuel supplies. 
However, Foretz et al. [63] found that metformin inhibits liver glucose synthesis independently of 
LKB1 or AMPK status. In addition, Kalender et al. [70] demonstrated that metformin can enhance 
glucose uptake in rat skeletal muscle cells and inhibit mTOR signaling independently of AMPK.  
These findings suggest that a metformin AMPK-independent mechanism of action that interferes 
directly with the cellular energy output, and does not modulate genes involved in gluconeogenesis 
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pathway, may exist [63]. Interestingly, the ataxia telangiectasia mutated (ATM) gene, a tumor 
suppressor gene involved in DNA repair and cell cycle control, was discovered to activate AMPK 
through LKB1 dependent and independent pathways [71,72]. 
4. The Pharmacokinetics of Metformin 
Metformin entry into the cell via passive diffusion is limited due its hydrophilic nature. Thus, 
metformin requires the use of cation transporters, such as the organic cation transporters (OCTs), to 
facilitate its cellular uptake [73]. Currently, OCT1 and OCT2 which are encoded by the SLC22A1 and 
SLC22A2 genes, respectively, are recognized as the major transporters for metformin and are highly 
expressed in the liver, gut, and kidneys [74]. For example, mice that are null for OCT1 exhibit a 
significant reduction in hepatic metformin uptake, suggesting that the OCT1 transporter is essential for 
metformin accumulation in the liver, which is the main target tissue of this drug [75]. In addition, 
microarry analysis has revealed that the degree of OCT1 expression can be variable when comparing 
tumor vs. normal human tissues, suggesting that therapeutic responses to metformin in cancer patients 
may differ depending on their tumor-type [76]. 
By contrast, many in vitro models (experimental cell lines that are immortalized) have low 
expression of OCTs, and thus require millimolar (mM) concentrations of metformin to elicit similar 
physiological effect in vivo [73]. Although reports indicate that this issue can be bypassed by 
enhancing the ectopic expression of OCTs cDNAs into target cells [77,78]. Nevertheless, a recent 
report by Segal et al. [79] has indicated that OCT1 is expressed in multiple ovarian cancer cell lines, 
and that siRNA-mediated knockdown of OCT1 expression attenuated the ability of metformin  
(0–10 mM) to inhibit their survival. 
Another important factor that may modulate the pharmacokinetics and therapeutic response to 
metformin are genetic variations in the OCT genes. To date, there have been at least 25 coding single 
nucleotide polymorphisms (cSNPs) identified in the SLC22A1 gene [80], many of which have been 
described to affect OCT1 function [81]. In addition, 14 polymorphisms in the SLC22A2 gene have 
been detected, and are implicated in regulating the renal clearance of metformin [82]. Such mutations 
may lead to complication with metformin toxicity, as 90% of metformin is cleared from the body 
within a few hours via the renal system. 
Moving forward it will be important to better characterize other candidate genes that may influence 
metformin uptake treatment success. One genome-wide association study conducted in the United 
Kingdom, found that favorable glycemic responses to metformin were associated within a locus of the 
ATM gene [83]. This was an interesting finding since ATM is a DNA-damage sensor that is also 
implicated in regulating metformin-induced activation of AMPK in rat hepatocyte cells [83].  
The effects of metformin on the ATM-AMPK cell cycle network may also explain some of 
chemopreventive proprieties (discussed in more detail below). 
5. Metformin Anticancer Properties 
The epidemiological evidences of the anticancer properties of metformin are supported by several 
molecular findings. Both AMPK-dependent and independent pathways have been proposed to mediate 
the anticancer effects of metformin treatment, which are described below. 
Metabolites 2013, 3 1058 
 
 
5.1. AMPK Dependent Mechanisms 
As mentioned, AMPK is a key sensor of cellular energy stress. Metformin treatment induces a 
perturbation in the AMP:ATP ratio checked by AMPK, that once activated, phosphorylates substrates 
which promote the catabolic processes and inhibit the anabolic processes to restore energy 
homeostasis. The first substrate inhibited by AMPK play a key role in lipogenesis [23,83,84]  
(Figure 2). The inhibition of fatty acid synthesis (FAS), reduces the consumption of ATP and their 
consequence oxidation produces new ATP molecules, such to restore the ATP levels reduced by the 
metformin action. AMPK suppresses the activity of FASN and ACACA. In effect, hepatic cell cultures 
treated with metformin showed a decrease in ACACA and FASN levels [68], while no effects were 
observed in hepatic and skeletal muscle cells that lack of LKB1 [85]. In addition, high levels of FASN 
and ACACA were found in several pre malignant cells. Moreover, tumors such as breast, colon, 
prostate, and ovarian cancer, are characterized by a high rate of lipid metabolism. The de novo fatty 
acid synthesis is required for tumor formation and progression [28]. Not only lipid synthesis but also 
cholesterol synthesis play a pivotal role in the cancer cells metabolism. AMPK suppresses the activity 
of 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase, thus to inhibit also cholesterol synthesis 
(Figure 2). Based on these evidences, metformin induces a shift in the lipid and cholesterol metabolism 
that could deprive pre-malignant and malignant cells of several substrates important for their growth 
and proliferation. 
Figure 2. Metformin triggers multiple pathways to exert its anticancer activities. 
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The PI3K/Akt/mTOR pathways are often deregulated in a large number of tumors. In particular, the 
anti mTOR therapies are an emerging strategy for renal cell carcinomas and breast cancer treatment. 
Several growth factors and nutrients stimuli impinge the PI3K/Akt/mTOR pathways, thus to sustain 
cell growth and proliferation [86]. mTORC1, one of the two functional mTOR complexes, regulates 
the protein synthesis by directly activating two important target involved in this process, such as  
S6 kinase (S6K) and translation initiation factor 4E binding protein 1 (4EBP1) [87]. AMPK negatively 
regulates mTORC1 by (i) modulating the activity of tuberous sclerosis complex 2 (TSC2), that 
together with TSC1 form a tumor suppressor complex that inhibits mTOR, or (ii) through 
phosphorylation and inhibition of its binding partner Raptor [88–90] (Figure 2). Moreover, metformin 
has been reported to inhibit the tumor progression of renal cells carcinoma by inhibiting mTOR 
activity through AMPK modulation [91]. Interestingly metformin exerts antiproliferative activity on 
glioblastoma cells through the inhibition of Akt pathway [92], besides, the inhibition of Akt activity 
seems to be the molecular mechanism by which metformin inhibits DNA damage accumulation in 
Drosophila midgut stem cell [93]. 
Furthermore, metformin represses aromatase expression in primary human breast adipose stromal 
cells, through the inhibition of CREB regulated transcription co-activator 2 (CRTC2) mediated by 
AMPK [94] (Figure 2). Based on this evidence, metformin treatment could represent a strategy for 
hormone-dependent post-menopausal breast carcinoma treatment, but it could be also a strategy for 
preventing post-menopausal breast carcinoma onset. 
Activation of AMPK stimulates cell cycle arrest through p53/p21 axis [95] (Figure 2). Mutation of 
p53 on serine 18 impairs the ability of AMPK to induce cell cycle arrest [95]. In addition, the metabolic 
reprogramming induced by metformin seems to be p53 dependent. In effect, metformin selectively 
impairs p53-deficient tumor cells growth that unlike those carrying wild type p53 protein, are no able 
to reprogram their metabolism and become apoptotic [24]. Recently, metformin was reported to inhibit 
the proliferation of melanoma cell lines through the activation of the AMPK/p53 pathway [96]. 
Notably, metformin has been demonstrated to exert its anticancer action by increasing the DICER 
mRNA and protein levels in breast cancer cell lines (Figure 2). Metformin was no longer able to affect 
tumor engraftment in knock-down DICER cells [61]. As discussed, low levels of DICER were found in 
several tumors. Based on these evidences, the overexpression of DICER in cancer cell lines and the 
consequence change in their microRNAs profiling could be a possible anticancer mechanism of action 
mediated by metformin. Bao and colleagues confirmed the important role of metformin in microRNAs 
modulation. They indicated that pancreatic cell lines treated with metformin had re-expressed several 
microRNAs usually switched off in pancreatic cancer, such as let7, involved in regulation of Ras 
signaling [97], and the miR-200 family of microRNA, directly involved in epithelial to mesenchymal 
transition and in maintenance of the stem cell state [98]. In particular, they demonstrated  
that metformin inhibits tumor sphere formation by deregulating several cancer stem cell (CSC) markers 
(CD44, EpCAM, EZH2, Notch-1, Nanog and Oct4) in part through the up regulation of microRNAs [99]. 
Further evidences about metformin anticancer action and microRNAs modulation were also found  
in human pancreatic [100], esophageal squamous carcinoma [101], gastric [102] and prostate cancer  
cell lines [103]. 
Interestingly, metformin significantly increases the number of senescence-prone murine embryonic 
fibroblasts (MEFs) entering a senescent stage in response to DNA damages after doxorubicin 
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treatment. This phenomenon is in part due to the modulation of the microRNAs 200 family and  
miR-205 [104] (Figure 2). 
5.2. AMPK Independent Mechanisms 
The main action of metformin is to sensitize peripheral tissue to insulin, thereby reducing insulin 
and glucose plasma levels. Interestingly, low circulating insulin levels induce the production of insulin 
like growth factor binding protein 1 (IGFBP1) in hyperinsulimenic women with PCOS syndrome [105] 
(Figure 2). PCOS patients show insulin resistance, hyperinsulinemia, anovulation and hyper-androgenemia. 
The latter aspect is promoted by a synergist action between luteinizing hormone (LH) and estrogen 
produced by granulose cells under insulin like growth factors 1 (IGF1) stimulation [106]. Based on this 
evidence, the increase in IGFBP1 levels mediated by metformin could limit the binding between IGF1 
and their receptors (IGF1R) and consequently also the androgen production. Moreover, this metformin 
effect could synergize with the common anti androgen therapies, which are usually prescribed for 
metastatic prostate cancer treatment [107]. In addition, high levels of IGF-1 impair chemotherapy-induced 
apoptosis by activating the PI3K/Akt pathway (Figure 2). Inhibition of IGF1R sensitizes small cell 
lung cancer cell lines to the effects of etoposide and carboplatin combined treatment [108]. 
Quinn and colleagues found that metformin decreases lung tumorigenesis in liver IGF-I-deficient 
(LID) mice without affecting IGF-I levels. The authors suggested an IGF-I-independent mechanism of 
action exerted by metformin through the inhibition of circulating growth factors and local receptor 
tyrosine kinases (RTK) signaling in an AMPK independent way [109]. 
Metformin can also inhibit the PI3K/Akt/mTOR signaling pathway in an AMPK independent way 
by modulating Rag GTPase activity [70] (Figure 2) while, in lung tissue, metformin reduces the 
activity of mTOR by decreasing activation of IGFR1 and Akt [110]. Other several evidences show 
other possible metformin anticancer mechanisms of action. It was found to reduce chronic 
inflammatory response through the inhibition production of tumor necrosis factor alpha (TNFα) in 
human monocytes [111] (Figure 2). Moreover, it was demonstrated that metformin blocks the 
production of endogenous reactive oxygen species (ROS) by interfering the mitochondrial complex I 
activity [112]. In addition, metformin appears to sensitize cancer cells against further DNA damages 
through the modulation activity of checkpoint homolog kinase 2 (CHK2), which play an important role 
in mediating the DNA damage response of ATM [113,114] (Figure 2). 
Interestingly, Ma et al. [115] demonstrated that cancer cell responsiveness to metformin is 
influenced by the K-ras status. Indeed, they showed that metformin induces apoptosis in the K-ras 
mutant tumors, such as A549 and PANC-1, but not in the K-ras wild-type tumor, A431, in vitro. 
Recently, the Raf-ERK-Nrf2 axis and the subsequent down regulation of heme oxygenase-1 were 
proposed by Do and colleges to explain a new AMPK-independent metformin anticancer mechanism 
of action [116]. 
6. Metformin and Cancer Therapy 
Metformin has also been studied for antineoplastic activity in patients with established cancer.  
The anticancer effects of metformin are via insulin-dependent and insulin-independent mechanisms. 
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Although metformin has become an attractive stand-all agent for molecular chemoprevention, many 
studies have also found it has a significant benefit when combined with common chemo or radiation 
therapy. For example, metformin has been shown to increase the cytotoxicity of many 
chemotherapeutic agents, including cisplatin, carboplatin, doxorubicin, and paclitaxel, and enhance 
tumor-free remission in vivo [117]. The ability of metformin to prolong tumor remission is believed to 
be due to the ability of this drug to selectively kill cancer stem cells (CSCs, also known as tumor 
initiating cells) that are chemoresistant and may lead to future cancer reoccurrence [118,119]. Indeed, 
metformin was found to eliminate CD44+/CD24− CSCs and sensitize in mouse breast cancer 
xenografts to doxorubicin treatment, leading to a significant reduction in the dose of chemotherapy 
used and thereby reducing complications due to toxicity [118]. In addition, metformin treatment was 
shown to reduced the proliferation rate of tumor-initiating cell-enriched cultures isolated from human 
glioblastomas [92]. 
Radiation therapy is another popular treatment modality for cancer of lung, breast, and prostate 
origin. However, many tumors are resistant to even high doses of ionizing radiation (IR), which 
sparked research interest into identifying adjuncts to radiotherapy [120]. Interestingly, Sanli et al. [120] 
identified that IR treatment activated the ATM-AMPK pathway in a variety of cancer cell lines, and 
that AMPK activity was required for IR-mediated G2/M cell cycle arrest. In addition, combination 
treatment with IR and metformin further potentiated AMPK signaling and sensitized lung cancer cells 
to the cytotoxic effects of IR. This same group later identified that clinically achievable doses of 
metformin (low μM range) were able to enhance radiation responses in vivo by blocking tumor 
angiogenesis and Akt-mTOR signaling, as well as enhancing apoptosis through the ATM-AMPK 
pathway [121]. 
In contrast to metformin, radiotherapy has also been found to increase the proportion of CSCs that 
survive IR treatment, indicating that CSCs are radio resistant compared to normal tumor cells.  
A recent report has indicated that metformin pretreatment in human MCF7 breast cancer or mouse 
FSaII fibrosarcoma cells can eradicate radiation-resistant CSCs and enhance IR-induced growth delay 
in fibrosarcoma tumors [122]. This recapitulated earlier reports that both IR and metformin activate 
AMPK and inhibit the mTOR pro-survival pathway. 
There are several ongoing studies which look at the use of metformin in cancer therapeutics as 
documented by the National Cancer Institute (NCI). There are Phase I and II studies which look at the 
use of metformin in treatment of melanoma, chronic lymphocytic leukemia, glioblastoma multiforme, 
and cancers of the breast, pancreas, endometrium, and head and neck. 
7. Role of Metformin as a Chemoprevention Agent 
7.1. All Cancers 
Observational data including registries of patients with type II diabetes have suggested that use of 
metformin may be associated with a decreased cancer incidence. Ruiter and colleagues published a 
large cohort study which included over 2.5 million diabetic patients who were identified via pharmacy 
dispensing records. They found that patients using metformin had a lower incidence of cancer 
compared to those who used sulfonylurea (HR 0.90, 95% CI 0.88–0.91) [123] (Table 1). 
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Currie et al. [124] published a retrospective cohort study in the UK, which included more than 
100,000 patients from primary care practices, of which 8,392 had type II diabetes. All patients with or 
without diabetes who developed a tumor were followed for up to 19 years. Diabetes was stratified by 
treatment regimen and Cox proportional hazard models were used to compare all-case mortality from 
all cancers and from specific cancers. They found that cancer mortality increased in patients with 
diabetes compared to non-diabetic patients (HR 1.09, 95% CI 1.06–1.13). When analyzed according to 
type of cancer, mortality was increased in breast and prostate cancer but was decreased in lung cancer. 
However diabetic patients had a lower mortality rate than non-diabetic patients if they were treated 
with metformin (HR 0.85, 95% CI 0.78–0.93). Alternatively diabetic patients had a higher mortality 
than non-diabetic patients if they were treated with sulfonylurea (HR 1.13, 95% CI 1.05–1.21) (Table 1). 
Table 1. Role of metformin in cancer therapy and chemoprevention. 
Study Study Types Inclusion Results 
Franciosi, M 
2013 
PLoS One 
Meta analysis 
41 
observational 
12 RCT 
Observational studies 
which examined 
association between 
metformin exposure 
and cancer.  
RCTs which compared 
metformin and other 
hypoglycaemic agents 
Observational studies, metformin associated with: 
Decreased risk of death  
(6 studies, OR 0.65, 95% CI 0.53–0.80) 
Decreased all malignancies  
(18 studies, OR 0.73, 95% CI 0.61–0.88) 
Decreased liver cancer  
(8 studies, OR 0.34 95% CI 0.19–0.60) 
Decreased colorectal cancer  
(12 studies, OR 0.83, 95% CI 0.74–0.92) 
Decreased pancreas cancer  
(9 studies, OR 0.56, 95% CI 0.36–0.86) 
Decreased stomach cancer  
(2 studies, OR 0.83, 95% CI 0.76–0.91) 
Decrased esophageal cancer  
(2 studies OR 0.90 95% CI 0.83–0.98) 
In RCTs: 
No significant effect of metformin on death or 
malignancies 
Thakkar, B 
2013 
Metabolism 
Meta analysis 
13 case 
control 
9 cohort 
2 RCTs 
Studies that assess 
metformin and/or 
sulfonylurea effects on 
cancer risk in diabetic 
patients 
In observational studies, metformin use was 
associated with reduced risk of developing cancer: 
Cohort studies (RR 0.70, 95% CI 0.67–0.73) 
Case-control studies (OR 0.90 95% CI 0.84–0.98) 
In RCTs: 
No effect on developing cancer  
(RR 1.01 95% CI 0.81–1.26) 
Stevens RJ 
2012 
Diabetologia 
Meta analysis 
13 RCTs 
RCTs which compared 
metformin to another 
diabetic treatment or 
placebo/usual care, 
with minimum 500 
participants and 1 year 
follow-up 
In RCTs looking at cancer outcomes (11 studies): 
RR 1.02 (95% CI 0.82–1.26) (11 studies) 
In RCTs looking at all-cause mortality  
(13 studies): 
RR 0.94 (95% CI 0.79–1.12) 
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Table 1. Cont. 
Study Study Types Inclusion Results 
Soranna D., 
2012 
Oncologist 
Meta analysis 
17 
observational  
Observational studies 
of diabetic patients 
treated with metformin 
and/or sulfonylurea 
where risk of all 
cancers and specific 
cancer mortality was 
investigated 
Metformin associated with decreased RR of: 
All cancers (RR 0.61, 95% CI 0.54–0.70) 
Colorectal cancer (RR 0.64, 95% CI 0.54–0.76) 
Pancreatic ca. (RR 0.38, 95% CI 0.14–0.91) 
Sulfonylurea not associated with reduced RR 
Noto H., 
2012  
PLoS ONE 
Meta analysis 
Cancer 
Mortality: 
4 cohort  
2 RCTs 
Cancer 
Incidence: 
6 cohort 
2 case control 
2 RCTs 
Studies of diabetic 
patients taking 
metformin compared to 
those not taking 
metformin 
Metformin users compared to non users had: 
Lower cancer mortality  
(pooled RR 0.66, 95% CI 0.49–0.88) 
Lower cancer incidence  
(pooled RR 0.67, 95% CI 0.53–0.85) 
Lower colorectal ca. incidence  
(pooled RR 0.68, 95% CI 0.53–0.88) 
Lower HCC (pooled RR 0.20, 95% CI 0.07–0.59) 
Lower lung cancer  
(pooled RR 0.67, 95% CI 0.45–0.99) 
Home et al. [125] looked at the outcomes of patients enrolled in two specific randomized controlled 
trials, ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for 
Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes), which tested the safety and 
efficacy of metformin in comparison to sulfonylureas and rosiglitazone. These studies did not show 
statistically significant differences in cancer outcomes for patients treated with metformin. In ADOPT 
the hazard ratio for developing a serious adverse event malignancy (excluding non-melanoma skin 
cancers) was 0.92 (95% CI 0.63–1.35) when compared to rosiglitazone and was 0.78 (95% CI 0.53–1.14) 
when compared to glibencalmide. In RECORD, on a background of sulfonylurea, the hazard ratio of 
developing malignant neoplasm in metformin versus rosiglitazone group was 1.22 (95% CI 0.86–1.74). 
Although these studies suggest a trend for an association between metformin and risk of malignancy, 
there was no statistically significant association (Table 1). 
Five recent meta-analysis have pooled data from studies which look at the potential use of 
metformin in cancer prevention in diabetic patients [126–130]. The largest and most recent meta analysis 
included 12 randomized controlled trials which compared metformin and other diabetic medications, 
and 41 observational studies which examined the association between metformin and cancer.  
In randomized controlled trials, there was no significant association between metformin exposure and 
risk of cancer death or of malignancy [126]. The observational studies found a significant association 
between metformin exposure and risk of cancer death, OR 0.65 (95% CI 0.53–0.80) and all 
malignancies, OR 0.73 (95% CI 0.61–0.88). 
Similar to this study, another meta analysis included 24 studies which examined subjects with type 
II diabetes and the effects of metformin and/or sulfonylurea on risk of cancer [127]. They found that 
metformin was associated with reduced risk of cancer in both cohort (RR = 0.70, 95% CI 0.67–0.73) 
and case control (OR = 0.90, 95% CI 0.84–0.98) studies, but not in RCTs (RR = 1.01 95% CI 0.81–1.26). 
Metabolites 2013, 3 1064 
 
 
In the same study, data from 18 studies which examined the effects of sulfonylurea in cancer 
prevention found an increase in all-cancer risk in cohort studies (RR = 1.55, 95% CI 1.48–1.63), but 
there was no statistically significant effect in case-control or RCT studies. 
One meta analysis included only randomized controlled trials [128]. Results did not show a 
statistically significant benefit of metformin on cancer outcomes including incidence and mortality.  
In 11 randomized controlled trials which looked at cancer outcomes, the relative risk in patients 
randomized to metformin compared to a comparator was 1.02 (95% CI 0.82–1.26). In 13 randomized 
controlled trials which looked at all-cause mortality, the relative risk was 0.94 (95% CI 0.79–1.12). 
The authors identified limitations in the trials including heterogeneous comparator groups and short 
follow-up. Follow up varied in each study, ranging from 1 year to 10.7 years, and the results were 
reported according to 51,681 person-years. Another very important limitation is that none of the 
clinical trials were designed to look at cancer as the primary outcome. 
One meta-analysis included only prospective studies which investigated the risk of all cancers and 
specific cancer sites in patients with type II diabetes who used metformin and/or sulfonylurea [129].  
In 17 studies, the use of metformin was associated with a decreased relative risk of all cancer  
(RR 0.61, 95% CI 0.54–0.70). When subdivided by type of cancer, the relative risk for colon cancer 
was 0.64 (95% CI 0.54–0.76); for pancreatic cancer was RR = 0.38 (95% CI 0.14–0.91). There was no 
evidence of association between metformin and reduction of breast and prostate cancers. There was no 
decrease in the relative risk of all or any cancer in patients who were treated with sulfonylurea.  
Using Egger’s regression asymmetry test and funnel plot, the authors found that evidence for 
publication bias for metformin-cancer association was present. This brings about a very important 
point. Publication bias is a factor which must be taken into consideration when interpreting the results 
of any meta analysis. 
The first meta analysis to suggest a survival benefit with metformin use in diabetic patients included 
four cohort studies plus two randomized controlled trials (RR 0.66, 95% CI 0.49–0.88) [130]. 
Metformin users also had lower cancer incidence (pooled RR 0.67, 95% CI 0.53–0.85).  
When subdivided by cancer type, there was lower incidence of colorectal cancer (pooled RR 0.68, 
95% 0.53–0.88), hepatocellular carcinoma (pooled RR 0.20, 95% CI 0.07–0.59), and lung cancer 
(pooled RR 0.67, 95% CI 0.45–0.99). However, there were no statistically significant benefits of 
metformin in reducing incidence of breast, prostate, pancreatic, gastric, or bladder cancer. 
The association of cancer outcomes and mortality with metformin use has been found in 
observational and cohort studies. These studies, however, inherently have biases which can be 
addressed with the use of randomized controlled trials. For example, there is evidence that a majority 
of observational studies which look at metformin and cancer suffer from immortal time bias and  
time-window bias which can lead to an exaggerated treatment effect [131]. To date, as outlined above, 
there are no meta analysis of randomized controlled trials which have shown a statistically significant 
effect of metformin on cancer outcomes. However the randomized clinical trials which are included in 
these analyses do not examine cancer as the primary outcome. There is a need for randomized 
controlled trials which compare individual treated with metformin compared to those who are not, and 
which look specifically for cancer outcomes. 
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7.2. Colorectal Cancer 
A meta-analysis was published in 2011 which included 4 studies with more than 100,000 patients 
with type II diabetes who were treated with metformin and in whom colorectal cancer outcomes were 
reported [132]. A random-effects meta-analysis model was used to summarize their findings. 
Metformin treatment was associated with a significantly lower risk of colorectal cancer with RR = 0.63 
(95% CI 0.47–0.84). The authors concluded that further clinical trials are required to verify these 
results which suggest an association between metformin use and decreased colorectal risk (Table 1). 
7.3. Lung Cancer 
A case control study in Taiwan looked at National Health Insurance claims compared 19,624 cases 
of newly diagnosed diabetes patients with 78,496 controls who were matched in sex and age to cases 
and they were followed for 9 years [133]. A multivariate Cox model analysis did not show a significant 
increase in lung cancer in diabetes patients compared to controls (HR = 1.05). In patients who were 
treated with anti-diabetic medication, there was a 39%–45% decreased risk of lung cancer. This included 
patients treated with metformin, thiazolidinediones, or alpha-glucosidase inhibitors (Table 1). 
7.4. Hepatocellular Carcinoma 
A meta analysis which included 5 studies and 105,495 patients with type II diabetes was published 
by Zhang and colleagues [134]. The effects of metformin on risk of liver cancer were analyzed with a 
random-effects model. The risk of liver cancer risk was decreased by 62% in diabetic patients who 
were treated with metformin (OR 0.38, 95% CI 0.24–0.59). The risk of hepatocellular carcinoma in 
particular was assessed in 4 trials and was decreased by 70% in diabetic patients who were treated with 
metformin (OR 0.30, 95% CI 0.17–0.52) (Table 1). 
7.5. Breast Cancer 
Prevention of breast cancer incidence in diabetic patients on metformin has been studied in the large 
Women’s Health Initiative cohort study [135]. In this study, 3401 women with type II diabetes were 
compared for breast cancer incidence to women without diabetes. Diabetic women did not have a 
significantly higher incidence of breast cancer compared to non-diabetic women (HR 1.16, 95%  
CI 0.93–1.45). Interestingly, diabetic women treated with metformin had a lower incidence of breast 
cancer when compared to non-diabetic women who were not on metformin (HR 0.75, 95% CI 0.57–0.99). 
A nested case control study was conducted in Denmark which included 393 diabetic patients and 3930 
controls [136]. Patients on metformin were less likely to have a breast cancer diagnosis (OR 0.77, 95% 
CI 0.61–0.99) (Table 1). 
7.6. Ongoing Studies 
There are several ongoing studies which are looking to determine the role of metformin in cancer 
prevention. Currently there are 168 studies registered worldwide on clinicaltrials.gov. Out of these,  
77 are registered in North America, 52 in Europe, 14 in Asia, 8 in Africa, and 6 in South America. 
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Specifically by cancer site, there are 24 studies in breast cancer, 11 studies in prostate cancer, 7 studies 
in colorectal cancer and 4 studies in lung cancer along with many others. These studies include phase I, 
phase II, and phase III studies. 
8. Conclusions 
Conclusive evidence has shown that metabolic alteration is a key future of cancer cells. 
Furthermore, metabolic alteration is a multistep process which occurs through the spatial and temporal 
disabling of specific biochemical pathways. This is early driven by either loss of tumor suppressor or 
aberrant oncogenic activities which lead to altered metabolism. 
The anticancer activity of metformin which causes metabolic reprogramming of cancer cells 
through the modulation of non-coding RNAs, is filling the gap of mechanistic knowledge of the 
epidemiologic evidence showing that diabetic patients treated with metformin have reduced cancer 
incidence and cancer-related mortality. This is also well documented by the large number of ongoing 
clinical trials using metformin in cancer treatment. Additionally, this growing mechanistic evidence is 
providing a strong rationale for the implementation of chemoprevention trials whose success could 
have an enormous impact on the health worldwide. 
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